Editorial: Epitope discovery and Synthetic Vaccine design by Palatnik-de-Sousa, Clarisa Beatriz et al.
April 2018 | Volume 9 | Article 8261
Editorial
published: 18 April 2018
doi: 10.3389/fimmu.2018.00826
Frontiers in Immunology | www.frontiersin.org
Edited and Reviewed by: 
Marc H. V. Van Regenmortel, 
Centre National de la Recherche 
Scientifique (CNRS), France
*Correspondence:
Clarisa Beatriz Palatnik-de-Sousa 
immgcpa@micro.ufrj.br
Specialty section: 
This article was submitted to 
Vaccines and Molecular 
Therapeutics, 
a section of the journal 
Frontiers in Immunology
Received: 03 January 2018
Accepted: 04 April 2018
Published: 18 April 2018
Citation: 
Palatnik-de-Sousa CB, 
Soares IS and Rosa DS (2018) 
Editorial: Epitope Discovery 
and Synthetic Vaccine Design. 
Front. Immunol. 9:826. 
doi: 10.3389/fimmu.2018.00826
Editorial: Epitope discovery  
and Synthetic Vaccine design
Clarisa Beatriz Palatnik-de-Sousa1,2*, Irene da Silva Soares3 and Daniela Santoro Rosa2,4
1 Laboratório de Biologiae Bioquimica de Leishmania, Microbiologia Geral, Universidade Federal do Rio de Janeiro,  
Rio de Janeiro, Brazil, 2 Instituto de Investigação em Imunologia, Faculdade de Medicina, Universidade de São Paulo (USP), 
São Paulo, Brazil, 3 Department of Clinical and Toxicological Analyses, Universidade de São Paulo, São Paulo, Brazil, 
4 Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal de São Paulo (UNIFESP), São Paulo, 
Brazil
Keywords: vaccines, synthetic vaccines, epitopes, t-epitope vaccines, B-cell epitope vaccines, epitope data-
bank, immunoinformatics
Editorial on the Research Topic
Epitope Discovery and Synthetic Vaccine Design
Traditional and first generation vaccines are composed of live or fixed whole pathogens, while 
second generation vaccines include, among others, the native protein antigens purified from the 
pathogen. And furthermore, third-generation vaccines are comprised of DNA plasmids capable of 
expressing the sequence of the most important pathogen protein antigens in the host. During this 
evolution of vaccines, there has been a gain in safety, however, with a loss of efficacy that has been 
compensated for with the use of adjuvants.
The latest step in the evolution of vaccine formulations is the development of epitope vaccines. 
Epitopes are short amino acid sequences of a protein that can induce a more direct and potent 
immune response, than the response induced by the whole cognate protein (1).
Moreover, the strategy for developing epitope vaccines requires an accurate knowledge of the 
amino acid sequence of the immunogenic protein of interest. Therefore, since vaccines against 
parasite, bacteria, or virus infections and tumors require a cellular immune response for prevention, 
control, and cure, a strategy called Reverse Vaccinology (RV) was developed. The RV approach 
uses the information of the codon sequence contained in the DNA of the pathogen to obtain a 
complementary cDNA, and further translates it to obtain the sequence of the protein of interest. 
Once these proteins are inside the antigen-presenting cells (APC) of the host, they are processed. 
The T cell epitopes are then proteolytically cleaved from the protein, and further exposed by the 
MHC molecules of the APC surface, to interact with the receptors of T cells. Therefore, with the knowl-
edge of the primary sequence of the protein antigen, the epitopes can be identified by cloning the 
domains or smaller peptides of the protein separately and experimentally determining which one is 
more immunogenic, or alternatively, by screening the whole protein sequence using in silico predic-
tions programs [Fleri et al.; (2, 3)].
The structure of the MHC molecules on APC, MHC class I molecules have a single alpha chain 
that influences binding, and the binding groove lies between the alpha 1 and alpha 2 domains (Fleri 
et al.). Since the binding groove is closed, it can only accommodate shorter peptides (8–14 amino 
acids). The groove binding core has only nine amino acids. MHC class II molecules in contrast, have 
two chains, alpha and beta that influence binding. The binding groove is open and can accommodate 
longer peptides (13–25 amino acids) but the binding core has 9 amino acid residues with 0–5 residues 
flanking on each side. Only the alpha chain is variable in class I molecules, so the nomenclature 
is “HLA” followed by the locus A, B, or C, an asterisk, and the number of the allele it represents. 
For class II molecules, both the alpha and beta chains impact binding and both of their chains are 
variable for the DP and DQ loci. However, for the DR locus, only the beta chain is variable (Fleri 
et al.). For all the mentioned characteristics, MHC class II binding prediction is more challenging than 
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that for class I molecules. Based on different machine learning 
algorithms, several predictions were developed as tools to identify 
the T cell epitopes of the protein antigens [Fleri et al.; (2, 3)].
In contrast, for parasite, viral, bacterial infections and tumors, 
whose prevention control and cure requires the development of 
a potent antibody response, the problem is more complex. In 
fact, the majority of B cell epitopes are discontinuous epitopes 
composed of amino acid residues located on separate regions of 
the protein, and which are joined together by the folding of the 
chain (4). These groups of residues cannot be isolated as such 
from the antigen. Therefore, the strategy used for these cases 
is called structural based reverse vaccinology (SBRV), and it 
focuses on the use of monoclonal antibodies against the protein 
antigen. There are six complementary determining regions (4) 
or antigen-binding regions (ABRs) (5), in the antibody mol-
ecule that can interact with the antigen. An antigen-binding 
site, also called a paratope, which is a small region (of 10–15 
amino acids) is the part of the antibody that recognizes and 
binds to an antigen. However, each ABR differs significantly in 
its amino acid composition and tends to bind different types of 
amino acids on the surface of proteins. In spite of these differ-
ences, the combined preference of the six ABRs does not allow 
the epitopes to be distinguished from the rest of the protein 
surface. These findings explain the poor success of past and 
newly proposed methods for predicting protein epitopes (4, 5). 
SBVR strategy is used to study the interaction of the complex 
composed of the monoclonal antibody with the protein in order 
to identify to which amino acids of the antigen protein, the ABR 
or paratope of the monoclonal antibody binds. The objective of 
this approach is to elucidate the potential amino acid sequence 
of the discontinuous epitope indirectly. However, the search for 
the epitopes that interact with antibodies is a much more dif-
ficult task to which successful prediction algorithms are about 
non-existing. Consequently, this strategy has not achieved 
much success (4, 5).
The inability of synthetic linear peptides to effectively mimic 
the discontinuous epitopes is one of the reasons for the failure of 
many B cell synthetic vaccines to induce the synthesis of neutral-
izing antibodies. These facts partially explain why even though 
more than a thousand synthetic B cell peptides have been identi-
fied, only 125 of them have progressed to phase I, 30 of them to 
Phase II, and none of them have succeeded in phase III trials or 
have been licensed for human use (4).
Hence, while RV generally refers to the in  silico analysis of 
the entire pathogen genome to identify all the antigens that the 
pathogen is able to express, the SBRV refers to the approach 
which tries to generate a vaccine from the known crystallographic 
structure of the neutralizing antibodies bound to the epitopes (6).
In the case of infections that are preventable by an antibody 
response, the term antigenicity has frequently been confused with 
immunogenicity (7). In fact, the epitopes of some viral antigens 
are often wrongly considered as immunogens, when they are 
only antigens, since they can interact with a variety of antibodies 
raised against a virus, but they are not capable of inducing the 
synthesis of the neutralizing antibodies engaged in protection 
(7). Previously, it was thought, that if an antigenic epitope bound 
strongly to a neutralizing monoclonal antibody in vitro, it would 
be also able to induce the synthesis of neutralizing antibodies 
when used as a vaccine. However, this is not true (7).
Additionally, other concepts have been developed in association 
to the RV strategy (6). The concept of RV 1.0 is an approach based 
on bioinformatics and animal immunization and challenge used to 
determine which antigens are more appropriate for vaccination (8). 
In contrast, the concept of RV 2.0 refers to a strategy that obtains 
monoclonal antibodies from the few individuals that make a strong 
antibody response against natural infection. These monoclonal 
antibodies guide the vaccine design in the reversal direction of the 
normal flow of vaccines to anti-bodies (8).
Furthermore, the concept of “rational vaccine design” was 
used very often creating the expectation of having the same 
success as the strategy of “rational drug design” obtained before. 
However, the “rational drug design” is related to the development 
of chemical analogs that are perfect inhibitors of the active site 
of important vital enzymes of the pathogen. In contrast, investi-
gators involved in the development of the HIV vaccine claimed 
that they use the “rational vaccine design” whereas in fact they 
only improved the antigenic binding capacity of one epitope with 
respect to only one paratope, and not the immunogenic capacity 
of an epitope to elicit neutralizing antibodies. These conclusions 
generated strong criticism [Van Regenmortel; (9)].
In contrast, the present Research Topic uses the concept of 
“Epitope Discovery and Synthetic Vaccine Design” as illustrated 
by Kao and Hodges (1). These authors demonstrated that synthe- 
tic vaccines based on short peptides, which represent immuno-
genic epitopes are able to impair and even exceeded the protective 
potential of the native cognate whole protein. They found higher 
antibody titers directed to the receptor-binding domain of the 
Pilus A of Pseudomonas aeruginosa, which has 14 amino acids 
than to the whole pilin native protein. The titers against the 
native pilin of the animals immunized with the synthetic peptide-
conjugate were higher, than the titers of animals immunized with 
the whole pilin protein. In addition, the affinities of the anti-
peptide sera for the intact pilin receptor-binding domain were 
significantly higher than affinities of anti-pilin protein sera (1).
We support the development of epitope vaccines that combine 
immunoinformatics and experimental biological approaches 
(Alves-Silva et al.; Barbosa Santos et al.). We used an immuno-
informatic approach to improve the efficacy of existing vaccines 
composed of protein antigens that were selected according to 
their relevance in previous experimental biological results. Our 
results also showed that vaccines composed of the immunogenic 
domains, optimize and even exceed the protective potential 
induced by the whole protein (1). For instance, we achieved 33% 
optimization of vaccine efficacy by using a recombinant chimera, 
which contains the two domains that hold the most immunogenic 
epitopes of the Nucleoside hydrolase NH36 of Leishmania, instead 
of the whole NH36 protein (Alves-Silva et al.). These two domains 
(F1 and F3) hold the most potent epitopes for the generation of 
prophylactic protection against Leishmania (L.) amazonensis 
infection (Alves-Silva et al.). Vaccination with the NH36 protein 
reduces the lesion sizes by 55% (10). However, vaccination with 
the F1 and the F3 domains independently determined respective 
reductions of 70 and 77%, and the F1F3 chimera induced a reduc-
tion of 82% in the footpad lesion sizes (Alves-Silva et al.).
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This enthusiasm coming after the advent of immunoinformatic 
tools and the finding of epitopes via in silico predictions should 
not devalue the empirical foundations of all experimental science 
involved in the development of the vaccines that control diseases 
until present (6). On the contrary, both the empirical and in silico 
tools should be used together in the development of new synthetic 
epitope vaccines that offer advantages over traditional vaccines. 
They are chemically defined antigens free from deleterious 
effects. Additionally, in contrast to live-attenuated vaccines, they 
do not revert to virulence in immunocompromised subjects, 
and different from genetic vaccines, they do not involve ethical 
questions.
With this Research Topic, we believed we have made sig-
nificant contributions to the development of synthetic epitope 
vaccines that may help in the prevention, treatment, and control 
of infectious diseases and cancer.
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